A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is concern that patients may be remaining on selective serotonin reuptake inhibitors (SSRIs) longer than is clinically indicated. Previous research has explored patients' experiences of taking SSRIs and decisions about starting medication. There has been less research into patients' reasons for long-term use and their views and experiences of discontinuation. AIM: To explore patient experiences of and beliefs about their long-standing SSRI use and understand the barriers and facilitators to discontinuation. DESIGN: Face-to-face semi-structured qualitative interview study. SETTING: One group general practice in Southampton, UK. FINDINGS: Three overarching themes were identified: (i) patient uncertainty about the benefits of, and continued need for, SSRI medication; (ii) barriers to stopping, including fear of withdrawal symptoms and fear of relapse; and (iii) the importance of the GP's role in facilitating cessation. Uncertainty and fear about withdrawal symptoms and what patients would be like without their medication were key barriers to stopping, even among patients who felt no discernible benefit from taking SSRIs. Patients indicated a need to share the decision to stop with their GP. However, the majority of patients interviewed had received repeat prescriptions of SSRIs without being reviewed by the GP. CONCLUSIONS: Patients prescribed SSRI medication need to be reassured that, as with starting medication, thinking about or actually stopping medication is a task that will not be managed in isolation, but with the support of their GP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In MDD, some individuals have endorsed FIR following the discontinuation of antidepressants [23–25].”
From Fear of depression recurrence among individuals with remitted depression: a qualitative interview study (2024) · cites this paper as [24]
In the citing paper
“Beyond the physiological effects related to drug withdrawal, discontinuing antidepressants can be difficult for psychological reasons. These include worry of relapse, a perceived biochemical cause of depression, insufficient emotion regulation skills and coping strategies, need for social support, psychological dependence, and experience of previous unsuccessful discontinuation attempts.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [9]
Citations
Cites
Interpreting Qualitative Data Methods for Analysing Talk, Text and Interaction
Kleinsasser, R. C., & Silverman, D. (1997) · The Modern Language Journal · doi:10.2307/329190 · Cited by 6,866
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
National Collaborating Centre for Mental Health
Veale, D. M. (2006) · Research Portal (King's College London) · Cited by 941
The National Collaborating Centre for Mental Health
Kendall, T., & Pilling, S. (2004) · UCL Discovery (University College London) · Cited by 840
Pollock, K., Mechanic, D., & Grime, J. (2002) · BMJ · doi:10.1136/bmj.325.7366.687 · Cited by 106
Verbeek-Heida, P. M., & Mathot, E. F. (2006) · Chronic Illness · doi:10.1177/17423953060020020801 · Cited by 75
van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0921-x · Cited by 72
Changes in Self-Concept While Using SSRI Antidepressants
Knudsen, P., Hansen, E. H., Traulsen, J. M., & Eskildsen, K. (2002) · Qualitative Health Research · doi:10.1177/104973202129120368 · Cited by 65
Maxwell, M. (2005) · Chronic Illness · doi:10.1177/17423953050010010401 · Cited by 63
Cited by
Patient Barriers to and Enablers of Deprescribing: a Systematic Review
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M. S., & Wiese, M. D. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0106-8 · Cited by 536
“The medication classes/therapeutic groups studied were BZDs (5) [33–37], psychotropic medication (2) [38, 39], depression/anxiety medications [40], selective serotonin reuptake inhibitors (SSRIs) (2) [41, 42], donepezil [43], methadone [44], antiepileptics [45], hormone replacement therapy (HRT) (3) [46–48], proton pu…”
BackgroundInfluentialMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
“The proportion of patients with a new diagnosis prescribed an antidepressant (79%) was very similar to that in our study. This raises the question of how much influence the use of questionnaires actually has on the prescribing decision. It has already been established that patients are anxious regarding discontinuatio…”
ResultSelf-citationPeople's Attitudes, Beliefs, and Experiences Regarding Polypharmacy and Willingness to Deprescribe
Reeve, E., Wiese, M. D., Hendrix, I., Roberts, M. S., & Shakib, S. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12418 · Cited by 221
Palagyi, A., Keay, L., Harper, J., Potter, J., & Lindley, R. I. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0181-x · Cited by 130
Wiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
Marsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30331-1 · Cited by 106
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
Strategies to reduce use of antidepressants
Kendrick, T. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14475 · Cited by 96
“on the part of patients that the prescriber is responsible for initiating discussions about stopping long-term treatment.(23,49) Practitioners should not assume the patient will initiate a discussion about with-”
BackgroundSelf-citationMaund, E., Dewar-Haggart, R., Williams, S., Bowers, H., Geraghty, A. W. A., Leydon, G., May, C., Dawson, S., & Kendrick, T. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.107 · Cited by 90
“This theme was described in 14 studies (Karp, 1993; Knudsen et al., 2002; Hoogen, 2006; Verbeek-Heida and Mathot, 2006; Leydon et al., 2007; McMullen and Herman, 2009; Aselton, 2010; Dickinson et al., 2010; McKinney and Greenfield, 2010; Schofield et al., 2011; Buus et al., 2012; Eveleigh, 2015; Nygaard et al., 2015;…”
BackgroundInfluentialSelf-citationBosman, R. C., Huijbregts, K. M., Verhaak, P. F., Ruhé, H. G., van Marwijk, H. W., van Balkom, A. J., & Batelaan, N. M. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x686641 · Cited by 76
Huijbregts, K. M., Hoogendoorn, A., Slottje, P., van Balkom, A. J. L. M., & Batelaan, N. M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480456 · Cited by 68
Long-term prescribing of antidepressants in the older population: a qualitative study
Dickinson, R., Knapp, P., House, A. O., Dimri, V., Zermansky, A., Petty, D., Holmes, J., & Raynor, D. K. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483913 · Cited by 66
van Geffen, E. C. G., Hermsen, J. H. C. M., Heerdink, E. R., Egberts, T. C. G., Verbeek-Heida, P. M., & van Hulten, R. P. (2010) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2010.04.001 · Cited by 77
Luymes, C. H., van der Kleij, R., Poortvliet, R. K. E., de Ruijter, W., Reis, R., & Numans, M. E. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016637181 · Cited by 63
“Our findings are also consistent with a study on the deprescribing of selective serotonin reuptake inhibitors; this study included patients who had actually tried or discussed deprescribing with their GP and highlighted the importance of being monitored and knowing that there was a possibility to restart their medicat…”
ResultAmbresin, G., Palmer, V., Densley, K., Dowrick, C., Gilchrist, G., & Gunn, J. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.055 · Cited by 61
“clinical encounters (Leydon et al., 2007).”
Patient experiences of taking antidepressants for depression: A secondary qualitative analysis
Anderson, C., & Roy, T. (2013) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2012.11.002 · Cited by 59
Ancianos frágiles polimedicados: ¿es la deprescripción de medicamentos la salida?
Moral, E. G., Barroso, A. V., Gracia, L. J.-D., & Santana, M. D. C. G. (2012) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2012.01.003 · Cited by 100
Withdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care
Eveleigh, R., Muskens, E., Lucassen, P., Verhaak, P., Spijker, J., van Weel, C., Oude Voshaar, R., & Speckens, A. (2018) · BJGP Open · doi:10.3399/bjgpopen17x101265 · Cited by 51
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211067656 · Cited by 52
Eveleigh, R., Speckens, A., van Weel, C., Oude Voshaar, R., & Lucassen, P. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319872344 · Cited by 48
Patient-Centered Perspectives on Antidepressant Use: A Narrative Review
Gibson, K., Cartwright, C., & Read, J. (2014) · International Journal of Mental Health · doi:10.2753/imh0020-7411430105 · Cited by 46
“[75] conducted a qualitative study”
Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness
Tjia, J., Kutner, J. S., Ritchie, C. S., Blatchford, P. J., Kendrick, R., Prince‐Paul, M., Somers, T. J., McPherson, M. L., Sloan, J. A., Abernethy, A. P., et al. (2017) · Journal of Palliative Medicine · doi:10.1089/jpm.2016.0489 · Cited by 46
“This is important because patients often will not bring up their concerns about medication discontinuation unless first provided with an opportunity to do so by their prescriber.(7,16,17) Furthermore, some reports suggest that up to 90% of people are willing to try discontinuation of their medications if their doctor…”
BackgroundSrimongkon, P., Aslani, P., & Chen, T. F. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s160728 · Cited by 43
“48 Our study findings were therefore in line with previous findings which have also reported that perceived potential harmfulness (concerns) were significantly related to prior experience of ADRs.”
Heser, K., Luck, T., Röhr, S., Wiese, B., Kaduszkiewicz, H., Oey, A., Bickel, H., Mösch, E., Weyerer, S., Werle, J., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.016 · Cited by 38
Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT
Kessler, D. S., Burns, A., Tallon, D., Lewis, G., MacNeill, S., Round, J. A., Hollingworth, W., Chew-Graham, C. A., Anderson, I. M., Campbell, J., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22630 · Cited by 39
“Evidence suggests that some patients using SSRI antidepressants would prefer to stop but are afraid to do so(72) and that, when considering stopping the use of SSRIs, patients have a number of concerns about cessation that clinicians should attend to.(73,74) In a meta-ethnographic synthesis of qualitative evidence it…”
BackgroundLunghi, C., Antonazzo, I. C., Burato, S., Raschi, E., Zoffoli, V., Forcesi, E., Sangiorgi, E., Menchetti, M., Roberge, P., & Poluzzi, E. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s241780 · Cited by 41
Why do patients discontinue antidepressant therapy early? A qualitative study
Jaffray, M., Cardy, A. H., Reid, I., & Cameron, I. M. (2013) · European Journal of General Practice · doi:10.3109/13814788.2013.838670 · Cited by 36
A practitioner behaviour change intervention for deprescribing in the hospital setting
Scott, S., May, H. M., Patel, M., Wright, D. J., & Bhattacharya, D. (2020) · Age and Ageing · doi:10.1093/ageing/afaa169 · Cited by 36
Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence
Crowe, M., Inder, M., & McCall, C. (2022) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12850 · Cited by 32
“Participants in eight studies identified these categories (Bosman et al., 2016; Brijnath & Antoniades, 2017; Davies et al., 2018; Eveleigh et al., 2019; Guy et al., 2020; Leydon et al., 2007; Ridge et al., 2015; Verbeek- Heida & Mathot, 2006).”
BackgroundMethodPredicting and preventing relapse of depression in primary care
Moriarty, A. S., Castleton, J., Gilbody, S. M., McMillan, D., Ali, S., Riley, R. D., & Chew-Graham, C. A. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x707753 · Cited by 32
Adherence to anti-depressant medication: a medicine-taking career.
Buus, N. (2014) · Social Science & Medicine (1967) · doi:10.1016/j.socscimed.2014.11.010 · Cited by 24
“However, qualitative studies have documented unsatisfactory interactions between antidepressant medication users and healthcare professionals, e.g. Anderson and Roy (2013), Leydon et al. (2007) and van Geffen et al. (2011).”
BackgroundLinsky, A. M., Simon, S. R., Stolzmann, K. L., & Meterko, M. M. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2017.10.012 · Cited by 26
Starting antidepressant use: a qualitative synthesis of UK and Australian data
Anderson, C., Kirkpatrick, S., Ridge, D., Kokanović, R., & Tanner, C. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008636 · Cited by 30
Heser, K., Pohontsch, N. J., Scherer, M., Löffler, A., Luck, T., Riedel-Heller, S. G., Maier, W., Parker, D., Haenisch, B., & Jessen, F. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202068 · Cited by 29
Maroun, R. A., Thackeray, L. A., & Midgley, N. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1961-y · Cited by 22
Wentink, C., Huijbers, M. J., Lucassen, P. L., van der Gouw, A., Kramers, C., Spijker, J., & Speckens, A. E. (2019) · British Journal of General Practice · doi:10.3399/bjgp19x706001 · Cited by 19
Scholten, W., Batelaan, N., & Van Balkom, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320933404 · Cited by 17
Coe, A., Gunn, J. M., Fletcher, S. L., Murray, E., & Kaylor‐Hughes, C. (2023) · Primary Health Care Research & Development · doi:10.1017/s1463423623000038 · Cited by 24
“…(Bowers et al ., 2019; Sørensen et al ., 2022; Van Leeuwen et al ., 2021) (Maund et al ., 2019a; Sørensen et al ., 2022), fear of deprescribing (Leydon et al ., 2007; Maund et al ., 2019a; Verbeek-Heida and Mathot, 2006) and clinical inertia (Henke et al ., 2009) have caused a lack of…”
InfluentialInterventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2024) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 16
Patient values and preferences on polypharmacy and deprescribing: a scoping review
Forest, E. W., Ireland, M., Yakandawala, U., Cavett, T., Raman‐Wilms, L., Falk, J., McMillan, D. E., Linthorst, R., Kosowan, L., LaBine, L., et al. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01328-w · Cited by 14
“Some studies reported that participants felt it was difficult for patients to initiate communication about stopping medication with their healthcare provider [24], while many studies reported that patients expressed an interest in shared decision-making with respect to polypharmacy and/or deprescribing [19, 20, 31, 32…”
BackgroundKlein, N. S., van Rijsbergen, G. D., ten Doesschate, M. C., Hollon, S. D., Burger, H., & Bockting, C. (2017) · Depression and Anxiety · doi:10.1002/da.22598 · Cited by 14
“Studies show that GP guidance regarding the tapering of ADM varies widely (Bosman et al., 2016; Leydon et al., 2007; Verbeek-Heida & Mathot, 2006).”
BackgroundWentink, C., Huijbers, M. J., Lucassen, P. L., Kramers, C., Akkermans, R., Adang, E., Spijker, J., & Speckens, A. E. M. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0989-5 · Cited by 15
Meißner, C., Meyrose, A., & Nestoriuc, Y. (2024) · British Journal of General Practice · doi:10.3399/bjgp.2023.0020 · Cited by 14
Brijnath, B., Xia, T., Turner, L., & Mazza, D. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1375-2 · Cited by 15
“While the evidence is limited on how precisely to implement antidepressant discontinuation [34], unequivocally GPs have a strong role to play in the process as facilitators of safe discontinuation and managing discontinuation symptoms [35, 36].”
BackgroundBrijnath, B., & Antoniades, J. (2017) · Qualitative Health Research · doi:10.1177/1049732316651404 · Cited by 11
Meißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04941-3 · Cited by 11
Coutts‐Bain, D., Sharpe, L., Techakesari, P., Forrester, M., & Hunt, C. J. (2023) · Clinical Psychology Review · doi:10.1016/j.cpr.2023.102342 · Cited by 11
Southern, J., Elliott, P., & Maidment, I. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04851-4 · Cited by 9
Coe, A., Gunn, J. M., & Kaylor‐Hughes, C. (2022) · JMIR Research Protocols · doi:10.2196/42526 · Cited by 10
“…expected to trigger deprescribing: (1) initiation of and participating in shared decision-making with GP regarding antidepressant deprescribing [26,35,44,47]; (2) patient education (participants will be assessed for, and informed of, their eligibility to deprescribe on the basis of the stability…”
BackgroundChew-Graham, C. A., Shepherd, T. A., Burroughs, H., Dixon, K., & Kessler, D. S. (2018) · BMC Family Practice · doi:10.1186/s12875-018-0877-4 · Cited by 8
“[28, 29] In a meta-ethnographic synthesis of qualitative evidence it was found that patients were heavily engaged in negotiating a ‘medication career’ or ‘moral career’ [30] making choices about how to proceed with treatment and sense-making around their illness.”
BackgroundHuijbers, M. J., Wentink, C., Lucassen, P. L., Kramers, C., Akkermans, R., Spijker, J., & Speckens, A. E. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290965 · Cited by 7
Gumuchian, S. T., Boyle, A., Hazel, L. H., & Ellenbogen, M. A. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05588-4 · Cited by 6
Deprescripción de medicamentos en ancianos: paradojas y contradicciones
Moral, E. G., de Gracia, L. J., & Barroso, A. V. (2013) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(13)70506-1 · Cited by 11
Coe, A., Gunn, J. M., Allnutt, Z., & Kaylor‐Hughes, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078179 · Cited by 6
“Had any challenges become evident in participants’ experiences, then immediate revisions could have been made; however, no changes were required.”
BackgroundHealthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study
Bouarfa, S., Göttgens, W., Ligthart, S. A., Maarsingh, O. R., Vinkers, C. H., Ruhé, H. G., Bet, P. M., & Hugtenburg, J. G. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70051 · Cited by 5
Adecuación terapéutica en pacientes crónicos
Orueta, R., Sánchez-Oropesa, A., Gómez-Calcerrada, R. M., Arriola, M., & Nieto, I. (2015) · Revista Clínica de Medicina de Familia · doi:10.4321/s1699-695x2015000100005 · Cited by 8
Scholten, W., Muntingh, A., Batelaan, N. M., Draisma, S., de Jonge, M., & van Balkom, A. J. L. M. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000550 · Cited by 5
Prescripción prudente y deprescripción de fármacos como herramientas para la prevención cuaternaria
Santana, M. D. C. G., Moral, E. G., Barroso, A. V., & Gracia, L. J.-D. (2015) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc10(35)1021 · Cited by 4
Benáček, J., Martin-Key, N. A., Barton‐Owen, G., Metcalfe, T., Schei, T. S., Han, S. Y. S., Olmert, T., Cooper, J. D., Eljasz, P., Farrag, L. P., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.088 · Cited by 3
Dewar-Haggart, R., Müller, I., Bishop, F. L., Geraghty, A. W. A., Stuart, B. L., & Kendrick, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299676 · Cited by 3
“Patients should be encouraged to attend more face-to-face consultations to discuss management, long-term risks of antidepressant use, and continued support, should they wish to discontinue treatment [15,29,30,76,84].”
InfluentialSelf-citationCritiquing the Critique: Resisting Commonplace Criticisms of Antidepressants in Online Platforms
Sthamann, E., & McMullen, L. M. (2021) · Qualitative Health Research · doi:10.1177/10497323211040768 · Cited by 2
“Fear of experiencing such symptoms has the potential to result in long-term use of antidepressants that, in some cases, might not be warranted (Leydon et al., 2007).”
BackgroundRole of primary care in depression relapse: a qualitative study
Moriarty, A. S., Williams, E., McMillan, D., Gilbody, S. M., & Chew-Graham, C. A. (2024) · British Journal of General Practice · doi:10.3399/bjgp.2024.0384 · Cited by 2
Hughes, S., Lacasse, J. R., & Spaulding‐Givens, J. (2019) · Qualitative Social Work · doi:10.1177/1473325019868292 · Cited by 2
Case-based learning: safe withdrawal and tapering of antidepressants
(2023) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.196471 · Cited by 2
Writers, A. M. (2014) · Drugs & Therapy Perspectives · doi:10.1007/s40267-014-0113-9 · Cited by 1
The Patient and Service User Perspective
Collinson, S., & Gask, L. (2018) · Cambridge University Press eBooks · doi:10.1017/9781911623038.005 · Cited by 1
Biersack, K., Sattel, H. C., Schönweger, P., Kaspar, L., Lehnen, N., Gensichen, J. S., Henningsen, P., & the POKAL group (2025) · PLoS ONE · doi:10.1371/journal.pone.0293713 · Cited by 1
“…patient centred care [150] Patient-centredness of care [35] Advantages of telehealth use [128] Experience of treatment [36,44,45,73,122,149,152,163–167] Experience of medication [38] Experience of taking medication [129] Attitude to treatment [98] Attitudes towards care management [127] Report of…”
Thrasher, S. M. (2010) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16984594 · Cited by 1
Clinical and medico-legal risk implications of psychiatric diagnostic reclassification
Langford, A. E., & Barry, N. (2013) · Clinical Risk · doi:10.1177/1356262213516936
“In addition, the difficulty some patients have in ceasing to take such medication should not be forgotten.(5) Founding prodromol categories could also expand the risks of medication.”
BackgroundImproving interventions for physical activity and depression
Lambert, J. D. (2017) · Figshare
Kendrick, T., Gunn, J. M., & Tylee, A. T. (2018) · Cambridge University Press eBooks · doi:10.1017/9781911623038.008
Self-citationThe serotonin theory of depression: how the media got it all wrong
(2022) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2022.1.153955 · Cited by 1
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Gumuchian, S. T., Boyle, A., Kennedy, G., Wong, S. F., & Ellenbogen, M. A. (2025) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2025.2500981 · Cited by 1
“…eight published studies have examined fears of depression recurrence (FoDR), with most focused on understanding the role that FoDR plays in medication adherence or discontinuation (Eveleigh et al., 2019; Grime & Pollock, 2003; Leydon et al., 2007; Scholten et al., 2020; Van Geffen et al., 2011).”
Kendrick, T., Stuart, B. L., Bowers, H. M., Sadeghi, M. H., Hl, P., Dowrick, C. F., Moore, M. V., Gabbay, M., Leydon, G., Yao, G., et al. (2025) · Programme Grants for Applied Research · doi:10.3310/btbl3945 · Cited by 1
Self-citationMeißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A.-K., Falkenberg, I., Kircher, T., & Nestoriuc, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26598848
Gumuchian, S. T., Boyle, A., Hazel, L., & Ellenbogen, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.25264468
Meißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A.-K., Falkenberg, I., Kircher, T., & Nestoriuc, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26598851
Southern, J., Elliott, P., & Maidment, I. (2024) · Figshare · doi:10.6084/m9.figshare.26591072
Gumuchian, S. T., Boyle, A., Hazel, L., & Ellenbogen, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.25264376
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.001
Kaylor‐Hughes, C., Coe, A., Chondros, P., Densley, K., Fletcher, S. L., Chatterton, M. L., Hoyer, D., Chen, T. F., Ng, C. H., Mangin, D. A., et al. (2026) · JMIR Research Protocols · doi:10.2196/81858
“These studies have highlighted factors, such as patient willingness, feeling ready to stop, confidence to stop, fear of addiction, trust in health care providers, and support networks, as important facilitators of successful deprescribing [23,40,43-45].”
Self-citationPsychotherapy Compared to Pharmacotherapy
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_18
Metadata
- Authors
- Leydon, G. M., Rodgers, L., & Kendrick, T.
- Affiliations
- University of Southampton (GB)
- Venue
- Family Practice
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-13
- Volume
- 24
- Issue
- 6
- Pages
- 570-575
- ISSN
- 0263-2136 (ISSN-L)
- 1460-2229
- OpenAlex
- W2148801257
- Cited by
- 85
- References
- 13
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 5 · 2012: 2
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Family Practice (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- selective serotonin reuptake inhibitors, drug discontinuation, long-term antidepressant use, patient experience, patient uncertainty, withdrawal symptoms, shared decision-making, role of general practitioners, repeat prescriptions
- MeSH terms
- Adult, Antidepressive Agents, Depression, Female, United Kingdom, Group Practice, Humans, Interviews as Topic, Long-Term Care, Male, Middle Aged, Patients, Selective Serotonin Reuptake Inhibitors, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.